<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867747</url>
  </required_header>
  <id_info>
    <org_study_id>ZKS-121-09</org_study_id>
    <nct_id>NCT03867747</nct_id>
  </id_info>
  <brief_title>Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias</brief_title>
  <acronym>RAVENTA</acronym>
  <official_title>Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias (RAVENTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universit채tsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with refractory ventricular extrasystoles or tachycardia not eligible for catheter
      ablation will receive single fraction stereotactic body radiation therapy (cardiac
      radiosurgery) with 25 Gy.

      Investigators initiated this study to demonstrate that in at least 70% of the patients the
      planned cardiac radiosurgery may be performed without any interruption or treatment related
      interventional events within the first 30 days after treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: 30-day post-intervention safety defined as presence of both, radiosurgery
      delivery of the planned dose to the intended target area, and no possibly treatment related
      serious adverse events in the first 30 days after treatment.

      Secondary endpoints: evaluated at 1 year

        -  Changes in ventricular tachycardia episodes and ICD shocks

        -  Changes in antiarrhythmic medication due to treatment effects

        -  Occurrence of possibly treatment related adverse events in the first year after
           treatment (according to CTCAE v5.0)

        -  Changes in patient-reported quality of life (recorded as EQ-5D-5L)

        -  Overall survival

        -  Safety profile
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity analysed by Adverse Event (AE)- and Serious Adverse Event (SAE)-reports</measure>
    <time_frame>30 days after radiosurgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicity analysed by Adverse Event (AE)- and Serious Adverse Event (SAE)-reports</measure>
    <time_frame>12 months after radiosurgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular tachycardia burden reduction analysed by number of episodes and ICD shocks</measure>
    <time_frame>At the time of inclusion and 12 months after radiosurgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months after radiosurgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaire (EQ-5D-5L)</measure>
    <time_frame>At the time of inclusion and 12 months after radiosurgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Cardiac Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 Gy in a single fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cardiac Radiosurgery</intervention_name>
    <description>Image-guided stereotactic body radiation therapy</description>
    <arm_group_label>Cardiac Radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with structural heart disease and implantable cardioverter defibrillator
             (ICD)

          -  Age &gt; 18 years

          -  either

               1. Recurring symptomatic monomorphic ventricular tachycardia that requires ICD
                  intervention (e.g. shock or anti-tachycardia stimulation). At least 3 episodes
                  within the 3 months prior to inclusion or

               2. induction of symptomatic monomorphic ventricular tachycardia that requires ICD
                  intervention (e.g. shock or anti-tachycardia stimulation). Induction triggered by
                  ICD or during electrophysiology studies (EPS) or both, a) and b)

          -  Refractory to antiarrhythmic combination therapy

          -  Beside the cardiac conditions: No competing illness that would additionally limit the
             life expectancy to less than 6 months

          -  No prior radiation therapy in the thorax area

          -  No pregnancy and no active breastfeeding

          -  Ability to consent and consent to study participation

        Exclusion Criteria:

          -  ICD electrode malfunction of ICD readings outside reference range

          -  Lack of evidence of a myocardial scar (Computer tomography or magnetic resonance
             tomography for MRI-capable ICD aggregates or electrophysiological measurement)

          -  No possible induction of symptomatic monomorphic ventricular tachycardia
             non-persistent or persistent with delivery of ICD therapies such as antitachycardic
             pacing or shock

          -  Contraindication to radiosurgery (e.g. precise target volume definition not possible
             due to image artifacts created from a left ventricular assist device [LVAD])

          -  Inability to consent or missing or withdrawn consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik Bonnemeier, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juergen Dunst, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juergen Dunst, Prof.</last_name>
    <phone>+49431500</phone>
    <phone_ext>26501</phone_ext>
    <email>Juergen.Dunst@uksh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oliver Blanck, Dr.</last_name>
    <phone>+49431500</phone>
    <phone_ext>26501</phone_ext>
    <email>Oliver.Blanck@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinic Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-W체rttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judit Boda-Heggemann, MD</last_name>
      <phone>+49621383</phone>
      <phone_ext>6020</phone_ext>
      <email>judit.boda-heggemann@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel B체rgy, MD</last_name>
      <phone>+49621383</phone>
      <phone_ext>6020</phone_ext>
      <email>daniel.buergy@medma.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Judit Boda-Heggemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel B체rgy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris Rudic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juergen Dunst, Prof.</last_name>
      <phone>+49431500</phone>
      <phone_ext>26501</phone_ext>
      <email>Juergen.Dunst@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Oliver Blanck, Dr.</last_name>
      <phone>+49431500</phone>
      <phone_ext>26501</phone_ext>
      <email>Oliver.Blanck@uksh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Juergen Dunst, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Krug, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Mehrhof, MD</last_name>
      <phone>+493045557088</phone>
      <email>felix.mehrhof@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Leif-Hendrik Boldt, MD</last_name>
      <phone>+4930455653722</phone>
      <email>leif-hendrik.boldt@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Felix Mehrhof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leif-Hendrik Boldt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Juergen Dunst, Prof.</investigator_full_name>
    <investigator_title>Prof. Dr. med. Juergen Dunst</investigator_title>
  </responsible_party>
  <keyword>Ventricular Tachycardia</keyword>
  <keyword>Stereotactic Body Radiation Therapy</keyword>
  <keyword>Radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

